Global RNA Therapeutics Growth Opportunities

Global RNA Therapeutics Growth Opportunities

Future Growth Potential Driven by Co-Development Programs and Robust Clinical Trials for Diverse Disease Areas

RELEASE DATE
31-May-2022
REGION
North America
Research Code: PD2B-01-00-00-00
SKU: HC03544-GL-MR_26547
$2,450.00
In stock
SKU
HC03544-GL-MR_26547
$2,450.00

Pay by invoice

ENQUIRE NOW

Description

Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target “undruggable” pathways. Technologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues. Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry.

Spurred by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic modalities during the forecast period. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships. In the industry’s transition to personalized therapeutics, RNA developers are capitalizing on the high precision of RNA to treat untapped chronic disease areas such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They engage in co-development programs to improve the stability profile of RNA therapeutics by optimizing drug delivery carriers, such as lipid nanoparticles.

Scaling up the production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continuous manufacturing is anticipated to reduce the operational timeframe of RNA therapeutics production. Technology transfer and the outsourcing of crucial operations to contract development and manufacturing organizations (CDMO) catalyze the development of cost-effective and efficient models for RNA therapeutics.

This Frost & Sullivan research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities. The research service highlights the following:
•     RNA therapeutics market size, including key segments from 2022 to 2027
•     Advancements in bioprocessing, modalities, and technologies that are shaping the market
•     Current and future R&D, investment outlook, and trends

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the RNA Therapeutics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Segmentation

Research Methodology

Key Takeaways

Growth Metrics

Growth Drivers

Growth Restraints

Key Trends

Key Disease Indications

Pipeline Snapshot for 2021

Value Chain—Key Stakeholders

Value Chain—Key Stakeholders (continued)

Notable Stakeholders Driving Disruption

Regional Snapshot of Manufacturers

Strategies to Meet SM Manufacturing and Supply Needs

Evolving Role of Stakeholders in the Supply Chain

Evolving Role of Stakeholders in the Supply Chain (continued)

Holistic Changes in RNA Therapeutics Biomanufacturing

Distribution and Supply Framework

Key Partnership Themes

Notable Partnerships

Notable Partnerships (continued)

Notable mRNA Manufacturing Partnerships by Region—Europe

Notable mRNA Manufacturing Partnerships by Region—US

Forecast Assumptions

Revenue Forecast

Revenue Forecast Analysis

Percent Revenue Forecast by Product Type

Key Modalities Under Development

Competitive Environment

Market Share Analysis

Growth Opportunity 1—Increase Focus on Immuno-oncology to Meet the Demand for Tumor-specific Targeted Therapeutics

Growth Opportunity 1—Increase Focus on Immuno-oncology to Meet the Demand for Tumor-specific Targeted Therapeutics (continued)

Growth Opportunity 2—Optimize LNP Delivery to Address the Stability Issues of RNA Therapeutics

Growth Opportunity 2—Optimize LNP Delivery to Address the Stability Issues of RNA Therapeutics (continued)

Growth Opportunity 3—Expand CDMO Capabilities to Support Biopharmaceutical Companies

Growth Opportunity 3—Expand CDMO Capabilities to Support Biopharmaceutical Companies (continued)

Growth Opportunity 3—Expand CDMO Capabilities to Support Biopharmaceutical Companies (continued)

List of Exhibits

Legal Disclaimer

Related Research
Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target “undruggable” pathways. Technologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues. Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry. Spurred by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic modalities during the forecast period. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships. In the industry’s transition to personalized therapeutics, RNA developers are capitalizing on the high precision of RNA to treat untapped chronic disease areas such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They engage in co-development programs to improve the stability profile of RNA therapeutics by optimizing drug delivery carriers, such as lipid nanoparticles. Scaling up the production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continuous manufacturing is anticipated to reduce the operational timeframe of RNA therapeutics production. Technology transfer and the outsourcing of crucial operations to contract development and manufacturing organizations (CDMO) catalyze the development of cost-effective and efficient models for RNA therapeutics. This Frost & Sullivan research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities. The research service highlights the following: • RNA therapeutics market size, including key segments from 2022 to 2027 • Advancements in bioprocessing, modalities, and technologies that are shaping the market • Current and future R&D, investment outlook, and trends
More Information
Author Mrinal Kerhalkar
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PD2B-01-00-00-00